TABLE 3.
Experiment | Treatment |
Disease parametersa |
||||
DI (%) | FDS (%) | M (%) | RAUDPC (%) | IR | ||
C− | 0.00 ± 0.00b | 0.00 ± 0.00c | 0.00 ± 0.00c | 0.00 ± 0.00c | 0.00 ± 0.00b | |
V.d. | 100.00 ± 0.00a | 91.00 ± 1.91ab | 100.00 ± 0.00a | 42.36 ± 2.08a | 0.55 ± 0.07ab | |
V.d. + CrR14 | 100.00 ± 0.00a | 92.74 ± 2.21ab | 95.24 ± 4.76a | 42.54 ± 2.62a | 0.65 ± 0.05a | |
V.d. + CrR18 | 100.00 ± 0.00a | 95.50 ± 1.80a | 90.48 ± 6.15ab | 39.19 ± 1.99ab | 0.55 ± 0.08ab | |
V.d. + CrR04 | 100.00 ± 0.00a | 93.40 ± 2.99a | 78.57 ± 7.70ab | 39.84 ± 2.18ab | 0.60 ± 0.05ab | |
Experiment I | V.d. + MTR12 | 100.00 ± 0.00a | 88.29 ± 2.74abc | 80.95 ± 9.91ab | 33.86 ± 2.59ab | 0.80 ± 0.07a |
V.d. + MTR18 | 100.00 ± 0.00a | 80.19 ± 4.75bc | 71.43 ± 8.69ab | 31.67 ± 3.02b | 0.55 ± 0.05ab | |
V.d. + CMR01 | 100.00 ± 0.00a | 78.79 ± 2.85c | 52.38 ± 14.29b | 30.72 ± 2.18b | 0.55 ± 0.08ab | |
V.d. + CMR03 | 100.00 ± 0.00a | 86.07 ± 2.71abc | 66.67 ± 14.55ab | 32.25 ± 1.47b | 0.65 ± 0.08a | |
V.d. + CML04 | 100.00 ± 0.00a | 85.82 ± 3.34abc | 69.05 ± 5.67ab | 37.91 ± 2.00ab | 0.65 ± 0.05a | |
V.d. + CMR25 | 100.00 ± 0.00a | 91.17 ± 2.37ab | 80.95 ± 9.91ab | 35.71 ± 1.46ab | 0.85 ± 0.03a | |
C− | 0.00 ± 0.00c | 0.00 ± 0.00c | 0.00 ± 0.00b | 0.00 ± 0.00d | 0.00 ± 0.00b | |
V.d. | 90.48 ± 6.15ab | 68.49 ± 5.43a | 47.62 ± 9.91a | 26.76 ± 2.95a | 0.53 ± 0.05a | |
V.d. + MTR17a | 71.43 ± 15.31ab | 50.21 ± 7.88ab | 33.33 ± 10.29ab | 15.05 ± 2.81bc | 0.20 ± 0.09ab | |
V.d. + MTR17d | 95.24 ± 4.76a | 70.22 ± 3.93a | 23.81 ± 14.02ab | 23.04 ± 2.20ab | 0.40 ± 0.20ab | |
Experiment I I | V.d. + MTR17f | 85.71 ± 9.91ab | 64.79 ± 6.12a | 33.33 ± 14.51ab | 22.95 ± 2.67ab | 0.38 ± 0.17ab |
V.d. + MTR17g | 80.95 ± 6.73ab | 58.36 ± 6.85ab | 38.10 ± 11.34ab | 16.81 ± 2.84abc | 0.27 ± 0.12ab | |
V.d. + MTR17h | 52.38 ± 12.30b | 35.15 ± 7.58b | 4.76 ± 4.76b | 10.51 ± 2.58cd | 0.10 ± 0.04b | |
V.d. + MTR17b | 80.95 ± 9.91ab | 57.05 ± 6.52ab | 19.05 ± 6.73ab | 14.85 ± 2.03bc | 0.40 ± 0.18ab | |
V.d. + MTR17c | 76.19 ± 9.52ab | 49.66 ± 7.35ab | 23.81 ± 6.15ab | 11.73 ± 2.35c | 0.13 ± 0.06ab | |
V.d. + TRIANUM-P | 52.38 ± 6.74b | 33.45 ± 7.44b | 4.76 ± 4.76b | 7.88 ± 1.94cd | 0.20 ± 0.09ab |
aDisease parameters were evaluated periodically on the basis of external symptoms during a period of 24 days (in Experiment I) and 30 days (in Experiment II) after root drenching with Verticillium dahliae conidial suspension (20 mL of 5 × 106 conidia mL–1 per plant). One week prior to inoculation with V. dahliae, plants were root-drenched with bacterial suspension (20 mL of 108 cfu mL–1 of each isolate per plant); whereas TRIANUM-P was also included in experiment II and applied by root drenching (20 mL of 3 × 107 cfu mL–1 per plant). DI, (final disease incidence; FDS, (final disease severity; M, (mortality; RAUDPC, (relative area under the disease progress curve with reference to the maximum value potentially reached over each assessment period; IR, (isolation ratio. Each value represents the mean of 21 plants after combining the results of 3 replicated experiments (except from IR that represents the mean of 5 plants in total). Within experiments, values in columns followed by the same letter are not significantly different according to Tukey’s HSD test at P ≤ 0.05.